{"id":32459,"date":"2025-04-25T23:31:32","date_gmt":"2025-04-25T15:31:32","guid":{"rendered":"https:\/\/flcube.com\/?p=32459"},"modified":"2025-04-25T23:31:33","modified_gmt":"2025-04-25T15:31:33","slug":"anhui-ankes-allogeneic-car-t-therapy-utaa09-approved-for-r-r-b-all-trials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32459","title":{"rendered":"Anhui Anke’s Allogeneic CAR-T Therapy UTAA09 Approved for r\/r B-ALL Trials"},"content":{"rendered":"\n

China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009<\/a>) announced that its joint venture with PersonGen BioTherapeutics (Suzhou) Co. Ltd and PersonGenAnke Cellular Therapeutics Co., Ltd has secured clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for UTAA09 (UCAR-V\u03b41T), a CD19-targeted allogeneic CAR-T therapy. The approval applies to the treatment of relapsed\/refractory (r\/r) acute B-lymphoblastic leukemia (B-ALL).<\/p>\n\n\n\n

Technological Breakthroughs<\/strong>
UTAA09 stands out as the world\u2019s first allogeneic CAR-T product derived from single-donor peripheral blood collections. It incorporates three key technological advancements: a \u03b3\u03b4-T cell-based platform utilizing the V\u03b41T subset, which has inherent tumor-targeting properties; non-viral vector gene editing to enhance genomic safety; and an off-the-shelf cryopreserved formulation for immediate use. These innovations position UTAA09 as a significant advancement in cancer immunotherapy.<\/p>\n\n\n\n

Clinical Trial and Previous Recognition<\/strong>
The therapy received Breakthrough Therapy Designation from the NMPA in 2023 for r\/r B-ALL. This designation underscores the potential of UTAA09 to address unmet medical needs in patients with this aggressive form of leukemia.<\/a>-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced that its joint venture with…<\/p>\n","protected":false},"author":1,"featured_media":32466,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[482,21,62,1752,4033,997],"class_list":["post-32459","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-anke-biotechnology","tag-car-t","tag-clinical-trial-approval-initiation","tag-persongen-biotherapeutics","tag-persongenanke-cellular-therapeutics","tag-she-300009"],"yoast_head":"\nAnhui Anke's Allogeneic CAR-T Therapy UTAA09 Approved for r\/r B-ALL Trials - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced that its joint venture with PersonGen BioTherapeutics (Suzhou) Co. Ltd and PersonGenAnke Cellular Therapeutics Co., Ltd has secured clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for UTAA09 (UCAR-V\u03b41T), a CD19-targeted allogeneic CAR-T therapy. The approval applies to the treatment of relapsed\/refractory (r\/r) acute B-lymphoblastic leukemia (B-ALL).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32459\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anhui Anke's Allogeneic CAR-T Therapy UTAA09 Approved for r\/r B-ALL Trials\" \/>\n<meta property=\"og:description\" content=\"China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced that its joint venture with PersonGen BioTherapeutics (Suzhou) Co. Ltd and PersonGenAnke Cellular Therapeutics Co., Ltd has secured clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for UTAA09 (UCAR-V\u03b41T), a CD19-targeted allogeneic CAR-T therapy. The approval applies to the treatment of relapsed\/refractory (r\/r) acute B-lymphoblastic leukemia (B-ALL).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32459\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-25T15:31:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-25T15:31:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2501-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32459#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32459\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Anhui Anke’s Allogeneic CAR-T Therapy UTAA09 Approved for r\\\/r B-ALL Trials\",\"datePublished\":\"2025-04-25T15:31:32+00:00\",\"dateModified\":\"2025-04-25T15:31:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32459\"},\"wordCount\":185,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32459#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2501-1.webp\",\"keywords\":[\"Anke Biotechnology\",\"CAR-T\",\"Clinical trial approval \\\/ initiation\",\"PersonGen BioTherapeutics\",\"PersonGenAnke Cellular Therapeutics\",\"SHE: 300009\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32459#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32459\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32459\",\"name\":\"Anhui Anke's Allogeneic CAR-T Therapy UTAA09 Approved for r\\\/r B-ALL Trials - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32459#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32459#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2501-1.webp\",\"datePublished\":\"2025-04-25T15:31:32+00:00\",\"dateModified\":\"2025-04-25T15:31:33+00:00\",\"description\":\"China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced that its joint venture with PersonGen BioTherapeutics (Suzhou) Co. Ltd and PersonGenAnke Cellular Therapeutics Co., Ltd has secured clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for UTAA09 (UCAR-V\u03b41T), a CD19-targeted allogeneic CAR-T therapy. The approval applies to the treatment of relapsed\\\/refractory (r\\\/r) acute B-lymphoblastic leukemia (B-ALL).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32459#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32459\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32459#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2501-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2501-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Anhui Anke's Allogeneic CAR-T Therapy UTAA09 Approved for r\\\/r B-ALL Trials\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32459#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anhui Anke’s Allogeneic CAR-T Therapy UTAA09 Approved for r\\\/r B-ALL Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Anhui Anke's Allogeneic CAR-T Therapy UTAA09 Approved for r\/r B-ALL Trials - Insight, China's Pharmaceutical Industry","description":"China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced that its joint venture with PersonGen BioTherapeutics (Suzhou) Co. Ltd and PersonGenAnke Cellular Therapeutics Co., Ltd has secured clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for UTAA09 (UCAR-V\u03b41T), a CD19-targeted allogeneic CAR-T therapy. The approval applies to the treatment of relapsed\/refractory (r\/r) acute B-lymphoblastic leukemia (B-ALL).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32459","og_locale":"en_US","og_type":"article","og_title":"Anhui Anke's Allogeneic CAR-T Therapy UTAA09 Approved for r\/r B-ALL Trials","og_description":"China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced that its joint venture with PersonGen BioTherapeutics (Suzhou) Co. Ltd and PersonGenAnke Cellular Therapeutics Co., Ltd has secured clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for UTAA09 (UCAR-V\u03b41T), a CD19-targeted allogeneic CAR-T therapy. The approval applies to the treatment of relapsed\/refractory (r\/r) acute B-lymphoblastic leukemia (B-ALL).","og_url":"https:\/\/flcube.com\/?p=32459","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-25T15:31:32+00:00","article_modified_time":"2025-04-25T15:31:33+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2501-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32459#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32459"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Anhui Anke’s Allogeneic CAR-T Therapy UTAA09 Approved for r\/r B-ALL Trials","datePublished":"2025-04-25T15:31:32+00:00","dateModified":"2025-04-25T15:31:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32459"},"wordCount":185,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32459#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2501-1.webp","keywords":["Anke Biotechnology","CAR-T","Clinical trial approval \/ initiation","PersonGen BioTherapeutics","PersonGenAnke Cellular Therapeutics","SHE: 300009"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32459#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32459","url":"https:\/\/flcube.com\/?p=32459","name":"Anhui Anke's Allogeneic CAR-T Therapy UTAA09 Approved for r\/r B-ALL Trials - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32459#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32459#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2501-1.webp","datePublished":"2025-04-25T15:31:32+00:00","dateModified":"2025-04-25T15:31:33+00:00","description":"China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced that its joint venture with PersonGen BioTherapeutics (Suzhou) Co. Ltd and PersonGenAnke Cellular Therapeutics Co., Ltd has secured clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for UTAA09 (UCAR-V\u03b41T), a CD19-targeted allogeneic CAR-T therapy. The approval applies to the treatment of relapsed\/refractory (r\/r) acute B-lymphoblastic leukemia (B-ALL).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32459#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32459"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32459#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2501-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2501-1.webp","width":1080,"height":608,"caption":"Anhui Anke's Allogeneic CAR-T Therapy UTAA09 Approved for r\/r B-ALL Trials"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32459#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Anhui Anke’s Allogeneic CAR-T Therapy UTAA09 Approved for r\/r B-ALL Trials"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2501-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32459","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32459"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32459\/revisions"}],"predecessor-version":[{"id":32462,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32459\/revisions\/32462"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32466"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32459"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32459"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32459"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}